PM
CORT icon

Parametrica Management’s Corcept Therapeutics CORT Stock Holding History

Parametrica Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,154
Closed -$312K – 369
2017
Q3 		$312K Buy
+16,154
New +$241K 0.13% 179

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Parametrica Management's CORT Position: Q4 2017 in Review

Parametrica Management sold out of Corcept Therapeutics (CORT) in Q4 2017, closing a stake of 16,154 shares — an estimated $312K sold.

Parametrica Management first reported a position in CORT in Q3 2017 and held it in 1 quarter. The position peaked at $312K in Q3 2017. 190 funds tracked by Wall St. Rank hold CORT as of Q4 2017.

  • Parametrica Management reported no remaining Corcept Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Parametrica Management sold 16,154 Corcept Therapeutics shares in Q4 2017, an estimated $312K.
  • Parametrica Management first reported a position in Corcept Therapeutics in Q3 2017 and held it in 1 quarter.
  • Parametrica Management's Corcept Therapeutics position peaked at $312K in Q3 2017.
  • 190 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2017.

Based on Parametrica Management's 13F filing for Q4 2017, filed 1 Feb 2018.